Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, a NK-cell bispecific antibody targets EGFR-wild type represents a validated antigen expressed by various solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AFMD
Previous Symbol
CUSIPN/A
Phone49-62-2165-3070
Debt
Debt-to-Equity Ratio0.06
Current Ratio3.66
Quick Ratio3.63
Price-To-Earnings
Trailing P/E Ratio-4.37
Forward P/E Ratio-4.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.27 million
Price / Sales93.72
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.80 per share
Price / Book4.26
Profitability
EPS (Most Recent Fiscal Year)($0.78)
Net Income$-34,160,000.00
Net Margins-2,124.72%
Return on Equity-82.22%
Return on Assets-63.68%
Miscellaneous
Employees8,406
Outstanding Shares62,390,000
Market Cap$238.33 million
OptionableOptionable
Affimed (NASDAQ:AFMD) Frequently Asked Questions
What is Affimed's stock symbol?
Affimed trades on the NASDAQ under the ticker symbol "AFMD."
How were Affimed's earnings last quarter?
Affimed NV (NASDAQ:AFMD) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.05. The biopharmaceutical company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.30 million. Affimed had a negative return on equity of 82.22% and a negative net margin of 2,124.72%. View Affimed's Earnings History.
When is Affimed's next earnings date?
What price target have analysts set for AFMD?
3 brokers have issued 1-year price targets for Affimed's stock. Their predictions range from $4.00 to $5.00. On average, they expect Affimed's stock price to reach $4.6667 in the next year. This suggests a possible upside of 36.9% from the stock's current price. View Analyst Price Targets for Affimed.
What is the consensus analysts' recommendation for Affimed?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Affimed.
Has Affimed been receiving favorable news coverage?
Press coverage about AFMD stock has trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Affimed earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
Are investors shorting Affimed?
Affimed saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 2,158,711 shares, an increase of 32.3% from the November 15th total of 1,631,417 shares. Based on an average daily trading volume, of 687,929 shares, the days-to-cover ratio is presently 3.1 days. Approximately 4.8% of the company's stock are short sold. View Affimed's Current Options Chain.
Who are some of Affimed's key competitors?
Some companies that are related to Affimed include Puma Biotechnology (PBYI), Homology Medicines (FIXX), Athenex (ATNX), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), ImmunoGen (IMGN), Crinetics Pharmaceuticals (CRNX), Alder Biopharmaceuticals (ALDR), Lexicon Pharmaceuticals (LXRX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Aptinyx (APTX), AC Immune (ACIU) and Dynavax Technologies (DVAX).
Who are Affimed's key executives?
Affimed's management team includes the folowing people:
- Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 56)
- Dr. Florian H. M. Fischer, MD, CFO & Member of Management Board (Age 50)
- Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 54)
- Prof. Melvyn Little, Founder & Consultant
- Dr. Martin Treder, Chief Scientific Officer (Age 48)
Who are Affimed's major shareholders?
Affimed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (2.05%), Sio Capital Management LLC (0.89%), EAM Global Investors LLC (0.76%), Morgan Stanley (0.66%), Tekla Capital Management LLC (0.41%) and Baker BROS. Advisors LP (0.32%).
Which institutional investors are selling Affimed stock?
AFMD stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Baker BROS. Advisors LP, Renaissance Technologies LLC and Morgan Stanley.
Which institutional investors are buying Affimed stock?
AFMD stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Sio Capital Management LLC, EAM Global Investors LLC, Prescott Group Capital Management L.L.C., EAM Investors LLC and CIBC World Markets Inc..
How do I buy shares of Affimed?
Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affimed's stock price today?
One share of AFMD stock can currently be purchased for approximately $3.41.
How big of a company is Affimed?
Affimed has a market capitalization of $238.33 million and generates $2.27 million in revenue each year. The biopharmaceutical company earns $-34,160,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. Affimed employs 8,406 workers across the globe.
What is Affimed's official website?
How can I contact Affimed?
Affimed's mailing address is IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 49-62-2165-3070 or via email at [email protected]
MarketBeat Community Rating for Affimed (NASDAQ AFMD)
MarketBeat's community ratings are surveys of what our community members think about Affimed and other stocks. Vote "Outperform" if you believe AFMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AFMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
